Develop novel therapeutics for patients with treatment resistant glioma

为难治性神经胶质瘤患者开发新疗法

• 批准号: 8938149
• 负责人: Teri Kreisl
• 金额: $ 10.61万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938149
• 关键词: Accounting; Adjuvant Chemotherapy; Adoptive Immunotherapy; Adverse effects; American Cancer Society; Anesthesia procedures; Angiogenesis Inhibitors; Antineoplastic Agents; Biological Markers; Biotechnology; Blood - brain barrier anatomy; Brain; Brain Neoplasms; Characteristics; Clinic; Clinical; Clinical Investigator; Clinical Trials; Clinical Trials Design; Collaborations; Cytotoxic agent; Development; Drug Combinations; Drug Delivery Systems; Drug Kinetics; Excision; Glioma; Growth; Hypoxia; Image; Immunotherapy; Industry; Infiltrative Growth; Institutes; Investigation; Joints; Laboratories; Laboratory Research; Malignant Glioma; Malignant Neoplasms; Medical; Medical Research; Modality; National Cancer Institute; National Institute of Neurological Disorders and Stroke; Nervous System Neoplasms; Nervous System Trauma; Neuraxis; New Agents; Operative Surgical Procedures; Pathology; Patients; Peptide Vaccines; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Physical Medicine; Primary Brain Neoplasms; Radiation Oncology; Radiation therapy; Radiosurgery; Recurrence; Regimen; Relative (related person); Research; Resistance; Science; Scientist; Signal Transduction; Social Work; Spinal Cord Neoplasms; Staging; Surgical Oncology; Survival Rate; Techniques; Testing; Tissues; Toxic effect; Translational Research; Treatment Protocols; United States National Institutes of Health; Work; cellular targeting; chemotherapy; clinical care; effective therapy; follow-up; improved; multidisciplinary; neuro-oncology; neurosurgery; novel; novel therapeutics; outcome forecast; patient population; programs; temozolomide; tumor; tumor immunology; tumor progression

Clinicians and clinical investigators, along with their scientist colleagues, are looking for more effective and safer ways to treat brain tumors. When laboratory research shows us that a new treatment has promise, clinical investigators and clinicians test the new treatment in well-controlled and closely scrutinized treatment protocols called clinical trials. These trials are designed to answer two basic questions: Is this treatment safe? (usually Phase I trials) Is this treatment effective? (usually Phase II trials) By taking part in a clinical trial, patients make an important contribution to medical research and science. They may also benefit from treatments that usually are not available outside a clinical trial. Many different types of clinical trials are available including those using: Radiation therapy New anticancer drugs New drug combinations Immunotherapy The NeuroOncology Branch (NOB) at the National Institutes of Health (NIH) is a team of dedicated medical professionals and scientists working to develop new therapies for patients with primary brain and spinal cord tumors. NOB is a joint program of the National Cancer Institute (NCI) and the National Institute of Neurological Disorders and Stroke (NINDS). In 1999, NCI saw approximately 10 primary brain tumor patients per year. We now see more than 200 new primary brain tumor patients per year and more than 2,000 follow up patients per year. This expansion in patient numbers was enabled by the rigorous and ambitious building of a primary neurooncology clinical care/research team, and establishing an NIH-wide multidisciplinary Brain Tumor Clinic with active participation from various NCI Branches, NIH Institutes, and Clinical Center Programs (neuroradiology, neurosurgery, radiation oncology, laboratory pathology, rehabilitation medicine, social work, tumor immunology). Through extensive collaborations established with the pharmaceutical and biotechnology industry, as well as through the translational science being generated in the NOB laboratory, we have been able to create and activate more than 40 clinical trials within NOB. This large clinical patient population and large number of available clinical trials allow us to accrue between 200 to 250 glioma patients per year to clinical trials. Our current portfolio of investigations include novel agents that are considered molecularly targeted treatments and/or antiangiogenic strategies to treat resistant malignant gliomas. Some compounds are in very early stages of development being tested in the phase I setting to identify toxicities and describe the pharmacokinetics of the drug. Other regimens are being tested in the phase II setting to evaluate whether there is any signal of efficacy and to further define treamtent related side effects. We also are exploring immunotherapy approaches to brain tumors using peptide vaccine and adoptive immunotherapy treatments. One of these efforts is through a collaboration with our partners in the Tumor Immunology group of the Surgical Oncology Branch. A number of studies also include correlative investigations of tissue and imaging biomarkers for drug activity in the brain and body.

临床医生和临床研究人员以及他们的科学家同事正在寻找更有效，更安全的方法来治疗脑肿瘤。当实验室研究表明新的治疗方法有希望时，临床研究人员和临床医生通过良好控制和严格审查的治疗方案来测试新的治疗方法，称为临床试验。这些试验旨在回答两个基本问题：这种治疗安全吗？ （通常是I期试验）这种治疗方法有效吗？ （通常是II期试验）通过参加临床试验，患者为医学研究和科学做出了重要贡献。它们也可能受益于通常在临床试验之外无法获得的治疗方法。提供了许多不同类型的临床试验，包括使用：放射治疗的新抗癌药物新药组合免疫疗法免疫疗法在国家卫生研究院（NIH）的神经机学分支（NOB）是一支专门的医疗专业人员和科学家组成的团队，旨在开发针对原发性大脑和脊髓肿瘤患者的新疗法。 NOB是国家癌症研究所（NCI）和国家神经系统疾病与中风研究所（NINDS）的联合计划。 1999年，NCI每年约有10名原发性脑肿瘤患者。现在，我们每年看到200多名新的原发性脑肿瘤患者，每年有2,000多名随访患者。 This expansion in patient numbers was enabled by the rigorous and ambitious building of a primary neurooncology clinical care/research team, and establishing an NIH-wide multidisciplinary Brain Tumor Clinic with active participation from various NCI Branches, NIH Institutes, and Clinical Center Programs (neuroradiology, neurosurgery, radiation oncology, laboratory pathology, rehabilitation medicine, social work, tumor immunology).通过与制药和生物技术行业建立的广泛合作，以及通过NOB实验室中的转化科学，我们能够在NOB中创建和激活40多个临床试验。这项庞大的临床患者人群和大量可用的临床试验使我们每年可以在200至250名神经胶质瘤患者中进行临床试验。我们目前的研究组合包括新型药物，这些药物被认为是分子靶向治疗和/或抗血管生成策略，以治疗耐药性恶性神经胶质瘤。在I期设置中，有些化合物正在开发的早期阶段，以鉴定毒性并描述该药物的药代动力学。在II期设置中测试了其他方案，以评估是否存在疗效信号，并进一步定义treamtent相关的副作用。我们还使用肽疫苗和收养免疫疗法来探索脑肿瘤的免疫疗法方法。这些努力之一是与我们在外科肿瘤学分支的肿瘤免疫学组的合作伙伴合作。许多研究还包括对大脑和人体药物活性的组织和成像生物标志物的相关研究。